Ophthalmology

Not So Different: Why You Should Keep Your Eye on Ophthalmology Biosimilars

January 24, 2021

Podcast

We spoke with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, about the status of ophthalmology biosimilars and her opinions on what needs to be accomplished for these biosimilars to flourish.

Coherus CEO Discusses Post–COVID-19 Growth Prospects

January 21, 2021

Tony Hagen

Article

Coherus BioSciences CEO Dennis M. Lanfear discusses the company's biosimilar marketing prospects in 2021.

Prestige Biopharma Plots Biosimilar Growth Strategy

January 20, 2021

Tony Hagen

Article

Biosimilars will be the cornerstone for a leap into biologics development and commercialization, according to the CEO of Prestige Biopharma. Also, Innovent Biologics reaches a marketing agreement.

IGBA, Celltrion, Others Mark Biosimilar Advances

January 17, 2021

Tony Hagen

Article

The Center for Biosimilars® reports on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.

Opinion: Is the Ophthalmology Market Ready to Embrace Biosimilars?

January 16, 2021

Sonia T. Oskouei, PharmD, BCMAS, DPLA

Article

Samsung Bioepis has filed for FDA approval for a ranibizumab biosimilar candidate (SB11), and more ophthalmology biosimilars are in the pipeline.

Economists Probe Cost-Effectiveness of Biosimilars

January 7, 2021

Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Alvotech Breaks Ground for Biosimilar Development Facility

January 3, 2021

Tony Hagen

Article

An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.

Reviewers Consider "Totality of Evidence" for Mvasi

January 2, 2021

Deana Ferreri, PhD

Article

Providers should feel confident using Mvasi, a bevacizumab biosimilar, for all indications of the reference product (Avastin), reviewers stated.

Innovent Biologics Gains NMPA Approval for Additional Sulinno Indications

December 31, 2020

Tony Hagen

Article

China's National Medical Products Administration (NMPA) has cleared Innovent Biologics' adalimumab biosimilar for more indications.

Opinion: The Year Ahead in Biosimilar Potential

December 29, 2020

Tony Hagen

Article

Many firsts may be in store for the biosimilar industry in 2021, although it will be dogged by ongoing difficulties, Center for Biosimilars® Advisory Board members said.

x